A Phase 1 Study of CTIM-76 in People With Advanced Ovarian or Endometrial Cancer

Full Title

A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurring Ovarian Cancer and Other Advanced Solid Tumors

Purpose

Researchers want to find the best dose of CTIM-76 to treat advanced ovarian or endometrial cancer. The people in this study have ovarian or endometrial cancer that makes a protein called CLDN6. This protein may fuel cancer growth.

CTIM-76 binds to one protein on cancer cells and another on immune cells. CTIM-76 may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. CTIM-76 is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have CLDN6-positive ovarian or endometrial cancer that spread and keeps growing after treatment.
• Have recovered from the serious side effects of prior therapies before getting CTIM-76.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Roisin O’Cearbhaill’s office at 646-888-4227.